Show simple item record

dc.contributor.authorNanishi, Etsuro
dc.contributor.authorMcGrath, Marisa E
dc.contributor.authorO'Meara, Timothy R
dc.contributor.authorBarman, Soumik
dc.contributor.authorYu, Jingyou
dc.contributor.authorWan, Huahua
dc.contributor.authorDillen, Carly A
dc.contributor.authorMenon, Manisha
dc.contributor.authorSeo, Hyuk-Soo
dc.contributor.authorSong, Kijun
dc.contributor.authorXu, Andrew Z
dc.contributor.authorSebastian, Luke
dc.contributor.authorBrook, Byron
dc.contributor.authorBosco, Anna-Nicole
dc.contributor.authorBorriello, Francesco
dc.contributor.authorErnst, Robert K
dc.contributor.authorBarouch, Dan H
dc.contributor.authorDhe-Paganon, Sirano
dc.contributor.authorLevy, Ofer
dc.contributor.authorFrieman, Matthew B
dc.contributor.authorDowling, David J
dc.date.accessioned2022-08-09T13:50:52Z
dc.date.available2022-08-09T13:50:52Z
dc.date.issued2022-08-06
dc.identifier.urihttp://hdl.handle.net/10713/19537
dc.description.abstractThe SARS-CoV-2 Omicron variant evades vaccine-induced immunity. While a booster dose of ancestral mRNA vaccines effectively elicits neutralizing antibodies against variants, its efficacy against Omicron in older adults, who are at the greatest risk of severe disease, is not fully elucidated. Here, we evaluate multiple longitudinal immunization regimens of mRNA BNT162b2 to assess the effects of a booster dose provided >8 months after the primary immunization series across the murine lifespan, including in aged 21-month-old mice. Boosting dramatically enhances humoral and cell-mediated responses with evidence of Omicron cross-recognition. Furthermore, while younger mice are protected without a booster dose, boosting provides sterilizing immunity against Omicron-induced lung infection in aged 21-month-old mice. Correlational analyses reveal that neutralizing activity against Omicron is strongly associated with protection. Overall, our findings indicate age-dependent vaccine efficacy and demonstrate the potential benefit of mRNA booster immunization to protect vulnerable older populations against SARS-CoV-2 variants.en_US
dc.description.urihttps://doi.org/10.1038/s42003-022-03765-3en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relationThe authors declare that all data supporting the findings of this study are available within the supplementary information files (Supplementary Data 1 https://www.nature.com/articles/s42003-022-03765-3#MOESM4).en_US
dc.relation.ispartofCommunications Biologyen_US
dc.relation.urihttps://www.nature.com/articles/s42003-022-03765-3#MOESM4en_US
dc.rights© 2022. The Author(s).en_US
dc.titlemRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant.en_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s42003-022-03765-3
dc.identifier.pmid35933439
dc.source.journaltitleCommunications biology
dc.source.volume5
dc.source.issue1
dc.source.beginpage790
dc.source.endpage
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record